As of Mar 21
| +0.40 / +2.33%|
The 6 analysts offering 12-month price forecasts for Concert Pharmaceuticals Inc have a median target of 26.00, with a high estimate of 27.00 and a low estimate of 17.00. The median estimate represents a +48.23% increase from the last price of 17.54.
The current consensus among 5 polled investment analysts is to Buy stock in Concert Pharmaceuticals Inc. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.